CheckMate 078: Patient‐Reported Outcomes (PROs) With Nivolumab vs Docetaxel in Advanced Non‐Small Cell Lung Cancer (NSCLC): OA10
Sign Up to like & getrecommendations! Published in 2018 at "Journal of Thoracic Oncology"
DOI: 10.1016/j.jtho.2018.10.020
Abstract: Conclusion: We interrogated the characteristics of ERBB2 exon 20 insertions in a large cohort from single ethnicity. It demonstrated the response heterogeneity to afatinib among different ERBB2 exon 20 insertion subtypes. It highlighted the importance… read more here.
Keywords: reported outcomes; checkmate 078; outcomes pros; 078 patient ... See more keywords
Lung adenocarcinoma with ERBB2 exon 20 insertions: Comutations and immunogenomic features related to chemoimmunotherapy.
Sign Up to like & getrecommendations! Published in 2021 at "Lung cancer"
DOI: 10.1016/j.lungcan.2021.07.014
Abstract: BACKGROUND The genomic mutation and immune feature landscape of ERBB2 exon 20 insertion (ERBB2-ex20ins)-driven non-small cell lung cancer and the features associated with the response to chemoimmunotherapy are currently unknown. METHODS The genomic landscape of… read more here.
Keywords: lung adenocarcinoma; chemoimmunotherapy; erbb2 exon; erbb2 ex20ins ... See more keywords
ERBB2 exon 20 insertions are rare in Brazilian non‐small cell lung cancer
Sign Up to like & getrecommendations! Published in 2022 at "Thoracic Cancer"
DOI: 10.1111/1759-7714.14605
Abstract: ERBB2 exon 20 insertions may impact the clinical management of lung cancer patients. However, the frequency of ERBB2 exon 20 insertions in lung cancer patients in Brazil is scarce. Here, we analyzed 722 Brazilian non‐small… read more here.
Keywords: lung cancer; erbb2 exon; cancer; exon insertions ... See more keywords
Clinical significance of ERBB2 exon 16 skipping: analysis of a real-world retrospective observational cohort study
Sign Up to like & getrecommendations! Published in 2020 at "ESMO Open"
DOI: 10.1136/esmoopen-2020-000985
Abstract: Background ERBB2 exon 16 skipping is an alternatively spliced isoform of ERBB2, which was reported to lead to oncogenic activation of ERBB2 and could potentially cause tyrosine kinase inhibitor (TKI) resistance in non-small cell lung… read more here.
Keywords: cancer; cohort; exon skipping; erbb2 exon ... See more keywords